QuA Vodis aims to help biotechnology and pharmaceutical companies get where they are going. The company, whose name shouldn't be confused with the movie Quo Vadis, offers interim management, quality assurance system development and training, and regulatory assistance to firms engaged in human and veterinary medical research. Its main focus for consultations is to enable the organizations to maintain operations and quality with as little internal disruption as possible. QuA Vodis has experience working with products such as sterile injectibles, radiopharmaceuticals, and blood and tissue products.

Trubion Pharmaceuticals, Inc.company was founded in 1999 and is headquartered in Seattle, Washington. Trubion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases and cancer. The company, in a collaboration with Wyeth, is conducting a phase IIb clinical trial for its lead product candidate, TRU-015, for the treatment of rheumatoid arthritis. The company also offers TRU-016, a phase II/II clinical evaluation product and a novel CD37-targeted therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and certain autoimmune and inflammatory disease indications. It also has collaboration agreement with Wyeth for the development and commercialization of SBI-087 for the treatment of rheumatoid arthritis and SBI-087 for the treatment of systemic lupus erythematosus, as well as other therapeutics directed to CD20, an antigen that is a validated clinical target present on B cells.

Pfizer decided to put a Cork in it, the pharmaceutical giant made Ireland one of the world's largest manufacturers and exporters of pharmaceuticals. Pfizer Ireland Pharmaceuticals is part of the Pfizer Global Manufacturing division. Parent company Pfizer began operating in Ireland in 1969 with a citric acid manufacturing plant and now operates about a dozen Irish plants. Its manufacturing facilities are involved in the development, formulation, and bulk manufacture of human pharmaceuticals (especially cardiovascular drugs) and animal health care products, as well as sterile pharmaceutical products and active pharmaceutical ingredients.

Roche Diagnostics Corporation company was founded in 1998 and is headquartered in Indianapolis, Indiana. Roche Diagnostics Corporation operates as a subsidiary of Roche Holding AG. Roche Diagnostics Corporation offers diagnostic tests and systems. The company operates in the diagnostic areas of diabetes care, centralized diagnostics, applied science, molecular diagnostics, and point-of-care diagnostics. Its products include diagnostics tools that test for congestive heart failure, HIV, Hepatitis B and C, fertility, and diabetes diseases. The company supplies its products to researchers, physicians, patients, hospitals, and laboratories. It has facilities in Indiana, New Jersey, South Carolina, Colorado, New Hampshire, Puerto Rico, and California, as well as locations in Canada.

Ark Therapeutics is loading its boat with therapies that target cancer and vascular disease. The biotech company has one product on the market in the UK and the US -- Kerraboot, a wound dressing that treats chronic leg and foot ulcers. Lead candidate Cerepro has shown promise in extending the lives of brain tumor patients. And it has two other clinical-stage candidates that may treat cancer-related muscle wasting and prevent blood vessels from blocking after vascular graft surgery. The firm develops and markets its own products in key markets, such as Europe and the US; it largely develops drugs for indications where it has a good chance of getting the regulatory privileges of Fast Track or Orphan Drug status.

Emergent BioSolutions Inc. company was founded in 1998 and is based in Rockville, Maryland. mergent BioSolutions Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and immune-related therapeutics in the United States, the United Kingdom, and Vietnam. The company offers BioThrax, a vaccine for preventing anthrax infection. Its advanced stage product candidates, which are in Phase II through Phase IV clinical development, include Recombinant protective antigen vaccine that comprises a purified recombinant protein with an alum adjuvant; Anthrax Immune Globulin therapeutic for the treatment of symptomatic anthrax infection; tuberculosis vaccine to prevent tuberculosis; Typhella which is a single-dose, drinkable vaccine for typhoid; Hepatitis B therapeutic vaccine for treating chronic carriers of hepatitis B infection. The company's earlier stage development product candidates comprise advanced BioThrax vaccine; Anthrax monoclonal antibody therapeutic, a human monoclonal antibody therapeutic for patients who present symptoms of anthrax disease; Recombinant botulinum vaccine to protect against illness caused by botulinum toxin; and Chlamydia vaccine for administration to adolescents to prevent disease caused by clinically relevant strains of Chlamydia trachomatis. Emergent BioSolutions Inc. has collaborations with Sanofi Pasteur and United Kingdom Health Protection Agency.

Molecular Insight Pharmaceuticals was founded in 1997 and is based in Cambridge, Massachusetts. Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States. The company develops Zemiva, a molecular imaging pharmaceutical product, which completed Phase II clinical trail for the diagnosis of cardiac ischemia or insufficient blood flow to the heart; and Trofex, a preclinical trail product for the detection of metastatic prostate cancer. Its molecular radiotherapeutic oncology product candidates under development include Azedra that completed Phase I clinical trail for the treatment of pheochromocytoma in adults and neuroblastoma in children; Onalta, a Phase II clinical trail product for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors; and Solazed, a preclinical trail product for the treatment of malignant metastatic melanoma. The company was formerly known as Biostream, Inc. and changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003.

Shionogi Pharma, Inc. company was founded in 1992 and is headquartered in Atlanta, Georgia. Sciele Pharma Inc. operates as a subsidiary of Shionogi & Co. Ltd. Sciele Pharma Inc., a pharmaceutical company, engages in acquiring, developing, marketing, and selling prescription products for patients primarily in the United States. It offers oral suspensions, tablets, and capsules, as well as products prescribed by the primary care physicians. The company provides cardiovascular and diabetes products that treat patients with high cholesterol, hypertension, high triglycerides, unstable angina, and Type 2 diabetes; pediatrics products, which treat allergies, asthma, cough and cold, and attention deficit and hyperactivity disorders; and products for the health and well-being of women, as well as for mothers and their babies. It develops glycopyrrolate oral solution, a treatment for chronic, moderate-to-severe drooling in pediatric patients.

Sirtris Pharmaceuticals can help keep you healthy in your golden years. The biopharmaceutical company focuses on developing drugs for treating ailments of aging. Its trial drug for the treatment of Type 2 Diabetes, which is associated with obesity, provides health benefits similar to calorie restriction without a change in diet. Founded in 2004, the company owns or licenses more than 150 patent applications for sirtuins, a class of enzymes. The activation of sirtuins helps reduce weight gain, as well improve glucose levels and insulin sensitivity. Sirtris filed an IPO in 2007, but was then acquired by GlaxoSmithKline (GSK) the following year.

AERES Biomedical Ltd. company was founded in 1999. AERES Biomedical develops therapeutic antibodies. The biopharmaceutical research company has developed more than 20 antibody candidates though collaborative partnerships with other biotech and pharmaceutical companies, many of which are in clinical trial stages. ABC-48 (an antibody for the treatment of deep vein thrombosis) and ABC-120 (an antibody for treating malaria) are two of the company's top candiates. AERES' products target debilitating and life-threatening illnesses, such as infectious, inflamatory, and cardiovascular diseases.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.